Sodium–Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia : A Population-Based Cohort Study
Authors' conclusion
Under conventional statistical criteria, a risk for dementia between 2.5 percentage points lower and 0.6 percentage point greater for SGLT2 inhibitors than for dulaglutide was estimated to be highly compatible with the data from this study. However, whether these findings generalize to newer GLP-1 RAs is uncertain. Thus, further studies incorporating newer drugs within these drug classes and better addressing residual confounding are required.
Study context
- Population
- Patients aged ≥60 years with T2D initiating SGLT2 inhibitors or dulaglutide; South Korea National Health Insurance Service data, 2010–2022matched cohort
- Participants
- 12,489 vs 1,075
- Comparison
- SGLT2 inhibitors vs dulaglutide
- SGLT2 inhibitorn = 12,489
- Dulaglutiden = 1,075reference
- Outcome
- Presumed clinical onset of dementia (onset defined as the year before dementia diagnosis)
- Follow-up
- 5-year
Methodological details1:2 propensity score-matched, nationwide
- 1:2 propensity score-matched
- Nationwide
Main finding
As reported in the abstract
Presumed clinical onset of dementia · 5-year risk; median follow-up 4.4 years
SGLT2 inhibitor
69
events
Dulaglutide
43
events
Each group vs dulaglutideRisk difference, percentage point (95% CI)
SGLT2 inhibitor
−0.91(−2.45 to 0.63)
Each group vs dulaglutideRisk ratio (95% CI)
SGLT2 inhibitor
0.81(0.56–1.16)
Original publication
Sodium–Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia : A Population-Based Cohort Study. Ann Intern Med. Published 27 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →